Furthermore, glioma samples (both LGGs and GBM) with an IDH1-mutant type have lower risk scores than IDH1wild-type samples, and the risk scores in LGGs with IDH1-mutant and 1p/19q codeletion samples have lower risk scores than IDH1-mutant and 1p/19q non-codeletion samples (Figure 9F). This evidence concerns the gene IDH1 and glioma.